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ABSTRACT
Objective: The study was designed to evaluate the C-Kit expression and also to assess the relationship with various clinicopathological characteristics 
in oral squamous cell carcinoma (OSCC) patients.
Methods: A total number of 102 formalin-fixed paraffin-embedded retrospective tissue samples were collected, in which (n =84) were histologically 
confirmed for OSCC, oral epithelial dysplasia (OED) (n=9), and control group (n=10) and studied immunohistochemically. The baseline characters 
and the correlation between the protein expression and clinicopathological parameters were analyzed. The survival analysis was performed using 
Kaplan-Meier Survival Method.
Results: OSCC exhibited C-Kit protein expression positivity of 6% and OED with 11.11% with no expression of this protein in control patients. Overall 
survival analysis showed that patients with negative expression had a better survival than patients with positive expression. However, we found that 
expression pattern of C-kit did not correlate with various clinicopathological characteristics.
Conclusion: Vast amount of study has to be still performed to under the mechanism of OSCC in C-KIT Expression to enhance the prognosis of OSCC 
patients in the near future.
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INTRODUCTION
Head and neck cancer is one of the most common cancers which ranks 
sixth among all other cancers [1]. Oral cancer is considered as the major 
problem in the developing countries and as well in other developed 
countries. However, approximately 2,74,300 cases are newly diagnosed 
oral cancer every year in which almost two-thirds of the populations 
are diagnosed in the developing countries [2]. In India, oral squamous 
cell carcinoma (OSCC) ranks third among the frequent cancers with 
an annual incidence of 52,000 patients and a mortality of 77% in 
developing nations. However, it is also found that OSCC is considered 
as most commonly occurring malignant disorder among the Southeast 
Asian populations [3]. In spite of the drastic improvement in therapeutic 
treatment, the 5-year survival rate is reported to be poor comprising 
of about 50–60%, specifically due to the fact that most of patients are 
resistant to chemotherapy [4-6]. In India, oral cancer is most commonly 
found among men rather than women populations. Tobacco and alcohol 
consumption is considered as a major risk factor for the cause of OSCC. 
However, socioeconomic status people show the higher incidence rate 
for causing oral cancer among which low socioeconomic status people 
are prone to higher risk of developing oral cancer [7].
CD117 is encoded by the proto-oncogene C-Kit, which is a transmembrane 
protein belonging to the Type III subfamily of the receptor tyrosine 
kinases that bind to the stem cell factor and also an most important 
regulator in the growth of the cells [8,9]. However, it is also known 
that CD117 plays a very important mechanism in melanogenesis, 
hematopoiesis, spermatogenesis, and carcinogenesis as well. In addition, 
CD117 has been expressed in various normal cells types such as mast 
cells, germ cells, melanocytes, and breast epithelial cells [10]. CD117 has 
been studied in different types of tumors such as breast cancer, non-small 
cell lung cancer, esophageal, hepatocellular carcinoma, respectively [10-
14]. Despite there are various studies performed in other cancers, it was 
found that CD117 plays an inadequate role in the oral cancer. Thus, the 
aim of our study was to investigate the immunohistochemical expression 
of CD117 in OSCC among the South Indian populations.
METHODS
Collection of samples
In the present investigation, the total number of samples included for 
the expression of C-Kit was 102 which includes both the males (n=73) 
and females (n=29). Retrospective formalin-fixed paraffin-embedded 
tissue (FFPE) samples were obtained and were clinically grouped as 
OSCC (n=84), oral epithelial dysplasia (OED, n=9), and control samples 
(n=9). Clinical data were obtained from the patients for the study 
purpose. The baseline characteristics of the study population were 
generated. The study was approved by the Institution Ethics Committee 
of (a) A.C.S Medical College, Chennai, (b) Sree Balaji Dental College and 
Hospital, and (c) Government Tertiary Care Centre, Chennai.
Immunohistochemical analysis
Retrospective FFPE samples were stained with hematoxylin-eosin. 
Stained slides were subjected to histopathological examinations 
and confirmed with the help of experienced oral pathologist from 
Private Dental College, Chennai, for the presence of tumor cells. 
Immunohistochemistry was performed with 3–5 μm sections of FFPE 
tissues. The sections were placed over 3-Aminopropyltriethoxysilane 
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coated slides (Sigma-Aldrich, USA) and dewaxed through three changes 
of xylene and hydrated through various descending grades (100% 
and 70%) of alcohol, respectively. The slides were gently washed 
with distilled water twice for 5 min each and were immersed in 
freshly prepared 3% hydrogen peroxide solution for 20 min to block 
endogenous peroxidase activity and again washed with distilled water 
twice for 5 min. Antigen retrieval was performed with 1M Tris-EDTA 
Buffer (pH – 9) in a pressure cooker and the slides were washed twice 
again with distilled water. Sections were preincubated with 2% bovine 
serum albumin (Sigma, US) for 30–40 min and then incubated in a moist 
chamber stored at 4°C. 10–20 μl of C-KIT primary antibody (PathnSitu, 
USA) was added to each section, and the samples were incubated in 
100% moisture chamber and stored at 4°C for overnight. In the 2nd day 
procedure, the slides were washed twice with freshly prepared ×1 
phosphate buffered saline (PBS) (pH -7.6) solution for 5 min each. 
The slides were then incubated with 10 μl of secondary antibody and 
kept in a moist chamber for 45 min and once again washed twice with 
freshly prepared ×1 PBS solution. For visualization, the sections were 
incubated with 5 μl of DAB chromagen for 5 min and washed with 
distilled water twice and counterstained using hematoxylin stain for 
45 s. The slides were dehydrated with different grades of alcohol and 
dipped in xylene for 5 min and mounted with DPX. The slides were 
directly captured using ProgRes Capture Pro 2.8.8 software (JENOPTIK 
optical systems) at ×4 objective magnification.
IHC scoring
The percentage of positive cells was estimated, and the staining 
intensity was recorded. The percentage of positively stained cells is 
as follows: 0%=0, 1–5%=1, 6–10%=2, and >10%=3. All the cells were 
counted in 10 random areas and presented as the percentage of positive 
cells. The staining intensity was recorded as negative, mild, moderate, 
and strong. A final expression score was calculated by multiplying 
labeling index score with intensity score, based on which further 
statistical analyses were performed as, the negative (score 0) were 
compared with the positive ones (scores 1–3). All the relevant clinical 
data, histopathological parameters, and immunohistochemical data 
were tabulated and subjected to appropriate statistical analysis.
Statistical analysis
All statistical analysis was performed with the help of IBM Statistical 
Package for the Social Sciences version 20.0 (Chicago, IL, USA). 
Numerical data were expressed as the mean±standard deviation. The 
comparisons of numerical data were performed by independent sample 
t-test, and association between factors, including clinicopathological 
variables, were assessed with the help of Chi-square or Fisher test. 
Hazard ratios (HRs) were assessed using Cox univariate analysis, and 
multivariate logistic regression was used to obtain odds ratio (OR) and 
confidence intervals (CI: 95%.). Overall survival analysis was performed 
using Kaplan-Meier method, and the statistical significance was 
analyzed with log-rank test. HRs were assessed using Cox univariate 
analysis, and multivariate survival analysis was carried out using Cox 
proportional hazards model. p<0.05 was considered to be statistically 
significant.
RESULTS
Patient’s study characteristics for proto-oncogene C-kit expression
A total number of 102 samples were examined for the expression of 
C-kit which included both the males (n=73) and females (n=29). The 
samples were clinically grouped as OSCC (n=84), OED (n=9), and 
control group (n=9). The mean age in the case of OSCC was 53.72±13.16 
in which the age of the patients ranged between 27 and 86 years, and 
the mean age of 50.66±10.59 was observed for OED with the age group 
ranging between 29 and 73 years. The control group comprising of the 
age group of 29–73 years showed a mean age group of 56.11±13.78. 
The baseline of the patient’s characteristics such as gender, chewing 
or smoking tobacco, and alcohol consumption was studied among the 
different study population and is tabulated in Table 1.
Immunohistochemical expression for C-kit
In the present investigation, based on the IHC scoring, only 6.0% of the 
patients (5 of 84) in the OSCC group showed a positive expression of 
the C-kit protein expression, whereas in the control group, it was 100% 
negative, and in OED group, though 11.11% (1 of 9) positive expression 
is seen (Fig. 1). Hence, we analyzed the correlation between the 
expression pattern of this protein and the clinicopathological conditions 
of the OSCC patient group and presented the findings. In the present 
investigation, we found a significant association of the expression 
of this protein with that of age (p=0.025), whereas less significant 
association is observed as far as other pathological parameters such 
as cancer location (p=0.138), smoking (p=1.000), alcohol (p=0.645), 
chewers with smokers (p=0.672), chewers with alcohol (p=0.363), 
smoking with alcohol (p=1.000), among all habits (p=0.644), gender 
(p=0.621), chewing (p=0.478), emphasis status (p=0.164), pattern 
of invasion (p=0.957), lymphovascular invasion (p=1.000), muscle 
involvement (p=0.062), progression stage (p=0.647), local recurrence 
(p=0.192), locoregional recurrence (p=1.000), Bryne grade (p=0.921), 
depth of invasion (p =0.571), treatment (p=0.069), and pathological 
identification (p=1.000) are concerned. The clinicopathological 
characteristics for C-Kit expression are summarized in Table 2.
Survival Analysis for C-kit
The survival analysis was performed using Kaplan-Meier Survival 
Method to find the survival status of the patients in terms of their 
positive and negative expression of this protein in OSCC groups. As far 
as C-Kit protein expression is concerned, negatively expressed patients 
showed better survival rate than positive expressed patients with 95% 
CI. Negatively expressed patients showed a survival of 27–34 months 
with the mean of 31±1.8, and it was 24–32 months with the mean 
of 28±2.1 in the case of positively expressed patients. The overall 
survival analysis using Kaplan-Meier survival with log-rank showed 
less significant association in C-Kit expression with that of survival 
(p=0.590) (Fig. 2). Using logistic regression model generated for proto-
oncogene C-kit, only age showed as influencing factor (OR=1.108, 
Table 1: Baseline clinical characteristics of recruited groups for 
C‑Kit expression
Parameters OSCC (%) n (%) OED (%) Control (%)
Number of patients (n=84) (n=9) (n=9)
Gender
Male 60 (71.4) 7 (77.8) 5 (55.6)
Female 24 (28.6) 2 (22.2) 4 (44.4)
Chewers
Yes 74 (88.1) 9 (100) 0 (0.0)
No 10 (11.9) 0 (0.0) 9 (100)
Alcohol
Yes 49 (58.3) 3 (33.3) 0 (0.0)
No 35 (41.7) 6 (66.7) 9 (100)
Smokers
Yes 52 (61.9) 6 (66.7) 0 (0.0)
No 32 (38.1) 3 (33.3) 9 (100)
Chewing with 
smokers
Yes 43 (51.2) 6 (66.7) 0 (0.0)
No 41 (48.8) 3 (33.3) 9 (100)
Chewing with 
alcohol
Yes 40 (47.6) 3 (33.3) 0 (0.0)
No 44 (52.4) 6 (66.7) 9 (100)
Smoking with 
alcohol
Yes 42 (50) 3 (3.3) 0 (0.0)
No 42 (50) 6 (66.7) 9 (100)
All habits
Yes 33 (39.3) 3 (33.3) 0 (0.0)
No 51 (60.7) 6 (66.7) 9 (100)
OSCC: Oral squamous cell carcinoma, OED: Oral epithelial dysplasia
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95% CI: 1.005–1.222, p=0.040). In multivariate Cox proportional 
hazards, regression analysis that adjusted for the effects showed that 
pathological identification (HR=0.345, 95%CI: 0.176–0.676, p=0.002) 
and progression stage (HR=0.356, 95%CI: 0.191–0.666, p=0.001) were 
considered as the risk factor for overall survival analysis.
DISCUSSION
CD117 is also known as c-Kit, proto-oncogene, or tyrosine-protein 
kinase kit which is a receptor in tyrosine kinase protein that is present 
in humans is encoded by KIT gene which plays an important role in cell 
survival, cell proliferation and cell differentiation. The overexpression 
of this protein can lead to cancer [15]. Several studies conducted on 
various types of cancers such as gastrointestinal cancers, renal cancers, 
small cell lung cancer, pancreatic cancers, and breast cancers have 
reported the overexpression of CD117. A study conducted by Miettinen 
et al. 2000 [16] showed 95% positive immune stained of C-Kit protein 
in gastrointestinal tumor and suggested the use of this protein as a 
biomarker for the diagnosis of GIST. Similarly, Beltran et al. 2006 [17] 
also showed a 100% positive expression in adenoid cystic carcinoma 
and Stemberger-Papic et al. 2014 [18] showed that C-Kit expression 
was seen in 81% of ovarian tumor samples indicating the prevalence of 
higher expressions in secretory organs.
There are certain types of cancers such as invasive ductal carcinoma 
breast [19] and thymic epithelial carcinoma [20], where only 46% CKIT-
positive expression was observed. At the same time, there are certain 
types of cancers, and Medinger et al. 2010 [21] have observed lower 
expression of the C-kit protein. Medinger et al. 2010 [21] have observed 
lower expression of the C-kit among which 17%  were observed in 
colorectal cancers, 35% in sarcomas, 36% in renal cell carcinoma 
Fig. 2: Kaplan‑Meier Survival analysis for C‑Kit expression
Table 2: Immunohistochemical expression of 
Clinicopathological characteristics for OSCC patients
Parameters C‑Kit positive p value
Age 5 0.025
Gender
Male 3 (60) 0.621
Female 2 (40)
Cancer location
Buccal mucosa 2 (40) 0.138
Tongue 3 (60)
Chewing
Yes 4 (80) 0.478
No 1 (20)
Smoking
Yes 3 (60) 1.000
No 2 (40)
Alcohol
Yes 2 (40) 0.645
No 3 (60)
Chewing with smoking
Yes 2 (40) 0.672
No 3 (60)
Chewing with alcohol
Yes 1 (20) 0.363
No 4 (80)
Smoking with alcohol
Yes 2 (40) 1.000
No 3 (60)
All Habits
Yes 1 (20) 0.644
No 4 (80)
T-stage
Yes 1 (20) 0.647
No 4 (80)
Local recurrence
Yes 2 (40) 0.192
No 3 (60)
Local regional recurrence
Yes 0 (0) 1.000
No 5 (100)
Treatment
Surgery alone 0 (0) 0.069
Surgery with prechemotherapy 
and preradiotherapy
1 (20)
Surgery with postchemotherapy 
and postradiotherapy
2 (40)
Palliative therapy 2 (40)
Emphasis status
Alive 1 (20) 0.164
Dead 4 (80)
Pathological identification
WDSCC 4 (80) 1.000
MDSCC 1 (20)
Lymphovascular invasion 
Yes 2 (40) 1.000
No 3 (60)
Muscle involvement
Yes 5 (100) 0.062
No 0 (0)
Not seen 0 (0)
Bryne grade
Grade 1 1 (20) 0.921
Grade 2 3 (60)
Grade 3 1 (20)
Depth of invasion
Grade 1 0 (0) 0.571
Grade 2 4 (80)
Grade 3 1 (20)
OSCC: Oral squamous cell carcinoma
Fig. 1: IHC Expression of C‑Kit (a) Normal Mucosa, ×20, (b) mild 
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patients, 17% in ovarian cancers, 21% breast cancer patients and 17% 
of the hepatocellular carcinoma patients. However, the expression 
pattern was also found to be lower in most of the carcinoma-like 
pleomorphic carcinoma (0.6%), squamous cell carcinoma (3.4%), large 
cell carcinomas (5.5%), adenocarcinomas (23.4%), and adenosquamous 
carcinomas (66.8%) as indicated in the study by Kriegsmann 2015 
[22]. In our study performed with CD117, in the oral cancer patients, 
we found only 6.0% expression in OSCC, 11.11% in OED cases, and 
100% negative expression in control cases. However, to the best of our 
knowledge, the current study was performed to evaluate the expression 
of C-Kit in OSCC patients belonging to the South Indian population. 
From our study, we could not find any contributing clinicopathological 
factors for OSCC patients in C-Kit protein expression due to the low 
sample size.
CONCLUSION
The current Immunohistochemical study was performed to identify the 
expression of C-Kit in OSCC, OED, and normal oral mucosa. However, it is 
found that C-Kit expression was not found to serve as a good prognostic 
factor in our study. Hence, further studies have to be performed on 
large-scale sample size with the help of prospective samples and as well 
as with various advanced molecular techniques which can also further 
help us to identify whether C-Kit can play as an important diagnostic 
and as well as prognostic tool in near future which can also pave a way 
in the advancement of targeted therapy in the near future for OSCC 
patients.
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